HUYA Bioscience Announces Agreement To Provide Schering- Plough With Drug Development Candidates From China

Collaboration will leverage HUYA’s growing Chinese bioscience network

San Diego, CA, USA – December 15, 2008 — HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Schering-Plough Corporation’s subsidiary, N.V. Organon. Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China. Read more

HUYA Bioscience Int’l Announces First Pre-Ind Outcome For A Development Stage Compound Sourced From China – Hbi-8000, Promising New Cancer Compound

FDA feedback validates HUYA’s Integrated Co-Development Model for China-sourced Drug Candidates

San Diego, CA, USA – April 14, 2008 — HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the outcome of the first pre-IND (Investigational New Drug) consultation with the U.S. FDA for a development-stage compound sourced from China. The new compound, HBI-8000 (CS055 / Chidamide), licensed from Chipscreen Biosciences, Ltd. of Shenzhen, China, shows promise for the treatment of a broad range of cancers and is nearing completion of a Phase I trial in China. HUYA holds exclusive development and commercialization rights to the compound worldwide outside of China, while Chipscreen maintains rights in China. Read more

HUYA Bioscience Int’l Announces Clinical Trial Milestones In China For Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

Progress validates HUYA’s innovative U.S./China pharmaceutical co-development model

San Francisco, CA, USA, IBC Conference – March 3, 2008 — HUYA Biosciences International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias. Read more